Shots:

• Audentes and NCH enter into a license agreement to develop AT702 designed to induce exon 2 skipping in DMD patients with exon 2 duplications and mutations in exons 1-5 in the dystrophin gene- with an expected initiation of P-I/II study in Q4’19
• The partners are also evaluating vectorized RNA knockdown & exon skipping for myotonic dystrophy type 1 (DM1) with an expected IND filling for AT466 in 2020. AT702 is AVV-antisense candidate targeted for patients with DMD
• Apart from the above collaboration- Audentes is conducting preclinical studies for AT751 and AT753 for DMD patients with genotypes amenable to exon 51 and 53 skipping

Ref: Audentes | Image: Twitter